GlassScriptPhysician profile
Emir Keric
NPI 1801814645
$6,938.30
in general payments reported to CMS, 2019-2025
38 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $956 · 2020: $389 · 2021: $1,015 · 2022: $993 · 2023: $1,207 · 2024: $1,272 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,584.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,261.07 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,050.11 | 2021-2025 | |
| Lilly USA, LLC | $834.11 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $664.35 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $424.67 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $318.17 | 2022-2025 | |
| Pfizer INC. | $283.92 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $249.20 | 2019-2023 | Belsomra, Verquvo, Steglatro |
| Amarin Pharma, INC. | $234.77 | 2019-2022 | |
| Amgen INC. | $202.10 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.17 | 2020-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $167.43 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $149.83 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $117.29 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $89.71 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emir Keric listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.